Arcellx stock steadies near $115 after Gilead’s $7.8 billion takeover bid — what traders watch next
Arcellx shares traded at $113.86 Tuesday after Gilead Sciences agreed to buy the company for $115 per share in cash plus a $5 contingent value right tied to anito-cel sales. The $7.8 billion deal awaits a tender offer launch and regulatory approvals, with the FDA’s decision on anito-cel expected by December 23, 2026.